BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15504110)

  • 1. ADAM disintegrin-like domain recognition by the lymphocyte integrins alpha4beta1 and alpha4beta7.
    Bridges LC; Sheppard D; Bowditch RD
    Biochem J; 2005 Apr; 387(Pt 1):101-8. PubMed ID: 15504110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.
    Bridges LC; Tani PH; Hanson KR; Roberts CM; Judkins MB; Bowditch RD
    J Biol Chem; 2002 Feb; 277(5):3784-92. PubMed ID: 11724793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrin alpha4beta1-dependent adhesion to ADAM 28 (MDC-L) requires an extended surface of the disintegrin domain.
    Bridges LC; Hanson KR; Tani PH; Mather T; Bowditch RD
    Biochemistry; 2003 Apr; 42(13):3734-41. PubMed ID: 12667064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of multiple beta1 integrins in cell adhesion to the disintegrin domains of ADAMs 2 and 3.
    Tomczuk M; Takahashi Y; Huang J; Murase S; Mistretta M; Klaffky E; Sutherland A; Bolling L; Coonrod S; Marcinkiewicz C; Sheppard D; Stepp MA; White JM
    Exp Cell Res; 2003 Oct; 290(1):68-81. PubMed ID: 14516789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements of MLD-containing disintegrins for functional interaction with alpha 4 beta 1 and alpha 9 beta1 integrins.
    Bazan-Socha S; Kisiel DG; Young B; Theakston RD; Calvete JJ; Sheppard D; Marcinkiewicz C
    Biochemistry; 2004 Feb; 43(6):1639-47. PubMed ID: 14769041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration.
    McGinn OJ; English WR; Roberts S; Ager A; Newham P; Murphy G
    Cell Biol Int; 2011 Oct; 35(10):1043-53. PubMed ID: 21332445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha4beta1 and alpha4beta7 integrins.
    Moyano JV; Carnemolla B; Domínguez-Jiménez C; García-Gila M; Albar JP; Sánchez-Aparicio P; Leprini A; Querzé G; Zardi L; Garcia-Pardo A
    J Biol Chem; 1997 Oct; 272(40):24832-6. PubMed ID: 9312081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchy of ADAM12 binding to integrins in tumor cells.
    Thodeti CK; Fröhlich C; Nielsen CK; Holck P; Sundberg C; Kveiborg M; Mahalingam Y; Albrechtsen R; Couchman JR; Wewer UM
    Exp Cell Res; 2005 Oct; 309(2):438-50. PubMed ID: 16061220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism.
    Cal S; Freije JM; López JM; Takada Y; López-Otín C
    Mol Biol Cell; 2000 Apr; 11(4):1457-69. PubMed ID: 10749942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotaviruses interact with alpha4beta7 and alpha4beta1 integrins by binding the same integrin domains as natural ligands.
    Graham KL; Fleming FE; Halasz P; Hewish MJ; Nagesha HS; Holmes IH; Takada Y; Coulson BS
    J Gen Virol; 2005 Dec; 86(Pt 12):3397-3408. PubMed ID: 16298987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective modulation of integrin-mediated cell migration by distinct ADAM family members.
    Huang J; Bridges LC; White JM
    Mol Biol Cell; 2005 Oct; 16(10):4982-91. PubMed ID: 16079176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1.
    Pepinsky RB; Mumford RA; Chen LL; Leone D; Amo SE; Riper GV; Whitty A; Dolinski B; Lobb RR; Dean DC; Chang LL; Raab CE; Si Q; Hagmann WK; Lingham RB
    Biochemistry; 2002 Jun; 41(22):7125-41. PubMed ID: 12033947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of divalent cations on the affinity and selectivity of alpha4 integrins towards the integrin ligands vascular cell adhesion molecule-1 and mucosal addressin cell adhesion molecule-1: Ca2+ activation of integrin alpha4beta1 confers a distinct ligand specificity.
    Day ES; Osborn L; Whitty A
    Cell Commun Adhes; 2002; 9(4):205-19. PubMed ID: 12699089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
    Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity.
    Bridges LC; Bowditch RD
    Curr Pharm Des; 2005; 11(7):837-47. PubMed ID: 15777238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disintegrin-like domain of the snake venom metalloprotease alternagin inhibits alpha2beta1 integrin-mediated cell adhesion.
    Souza DH; Iemma MR; Ferreira LL; Faria JP; Oliva ML; Zingali RB; Niewiarowski S; Selistre-de-Araujo HS
    Arch Biochem Biophys; 2000 Dec; 384(2):341-50. PubMed ID: 11368322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell adhesion to anosmin via α5β1, α4β1, and α9β1 integrins.
    Endo Y; Ishiwata-Endo H; Yamada KM
    Cell Adh Migr; 2018 Mar; 12(2):93-100. PubMed ID: 27715389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction.
    Eto K; Puzon-McLaughlin W; Sheppard D; Sehara-Fujisawa A; Zhang XP; Takada Y
    J Biol Chem; 2000 Nov; 275(45):34922-30. PubMed ID: 10944520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins.
    Mahimkar RM; Visaya O; Pollock AS; Lovett DH
    Biochem J; 2005 Jan; 385(Pt 2):461-8. PubMed ID: 15361064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAM28 as a target for human cancers.
    Mochizuki S; Okada Y
    Curr Pharm Des; 2009; 15(20):2349-58. PubMed ID: 19601836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.